NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Lorcaserin hydrochloride for the treatment of obesity and overweight

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Arena Pharmaceuticals (lorcaserin	Allied Health Professionals Federation
hydrochloride)	 Board of Community Health Councils in Wales
Patient/carer groups	British Cardiovascular Industry
Action Heart	Association
Afiya Trust	British National Formulary
Beat	Care Quality Commission
Black and Ethnic Minority Diabetes	Commissioning Support Appraisals
Association	Services
Black Health Agency	Department of Health, Social Services
 Blood Pressure Association 	and Public Safety for Northern Ireland
British Cardiac Patients Association	Diabetes UK Cymru
Counsel and Care	Healthcare Improvement Scotland
 Diabetes Research & Wellness 	Medicines and Healthcare products
Foundation	Regulatory Agency
Diabetes UK	National Association of Primary Care
 Equalities National Council 	 National Pharmacy Association
 Healthier Weight Centres 	NHS Alliance
Heart Care Partnership UK	NHS Commercial Medicines Unit
HEART UK	NHS Confederation
 Insulin Dependent Diabetes Trust 	Public Health Wales NHS Trust
Muslim Council of Great Britain	Scottish Medicines Consortium
 Muslim Health Network 	
 National Obesity Forum 	Comparator manufacturers
Network of Sikh Organisations	 GlaxoSmithKline (orlistat)
South Asian Health Foundation	Roche Products (orlistat)
Specialised Healthcare Alliance	
Surya Foundation	Relevant research groups
Weight Concern	British Society for Cardiovascular
5	Research
Professional groups	Cochrane Heart Group
Association for the Study of Obesity	Cochrane Metabolic & Endocrine
Association of British Clinical	Disorders Group
Diabetologists	Cochrane Peripheral Vascular Disease
British Association for Nursing in	Group
Cardiac Care	Cochrane Public Health Group
	CORDA

National Institute for Health and Clinical Excellence

Matrix for the technology appraisal of lorcaserin hydrochloride for the treatment of obesity and overweight Issue date: December 2012

Consultees	Commentators (no right to submit or appeal)
 British Association for Services to the Elderly British Cardiovascular Intervention Society British Cardiovascular Society British Cardiovascular Society British Cardiovascular Society British Geriatrics Society British Geriatrics Society British Heart Foundation British Hypertension Society British Heart Foundation Diabetes Specialist Nurses Dieticians in Obesity Management Faculty of Public Health Medicine National Centre for Eating Disorders National Diabetes Nurse Consultant Group National Heart Forum UK Primary Care Cardiovascular Society Primary Care Diabetes Society Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine Society for Cardiological Science & Technology Society for Vascular Technology Society for Vascular Nurses The Nutrition Society The Obesity Management Association United Kingdom Clinical Pharmacy Association Vascular Society 	 MRC Clinical Trials Unit National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust Evidence Review Group National Institute for Health Research Health Technology Assessment Programme School of Health & Related Research Sheffield (ScHARR) Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups None

National Institute for Health and Clinical Excellence

Matrix for the technology appraisal of lorcaserin hydrochloride for the treatment of obesity and overweight Issue date: December 2012

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Matrix for the technology appraisal of lorcaserin hydrochloride for the treatment of obesity and overweight Issue date: December 2012